Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • 16 Hour MAT Waiver Course for PAs

    Contains 34 Component(s)

    16 hour MAT waiver training course for physician assistants (PAs) who wish to apply for a waiver to prescribe buprenorphine. This is Part 2 of the 24 hour course requirement. Please visit pcssnow.org for Part 1 (8 hour course).

    Target Audience: 

    This activity will assist physician assistants (PAs) who wish to apply for a waiver to prescribe buprenorphine for the treatment of opioid use disorders.  

    In accordance with the Comprehensive Addiction and Recovery Act (CARA), PAs must complete 24 hours of specialized training to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. This activity will allow PAs to fulfill the 16 hour portion of the 24 hour MAT waiver training requirement.

    Educational Objectives:

    At the conclusion of this activity, learners should be able to:

    • Provide information about the pharmacology and clinical use of buprenorphine
    • Provide information on other approved antagonist and agonist medications to treat opioid use disorder
    • Provide resources needed to set up office-based treatment of opioid use disorder using buprenorphine  

    Fee: No cost 

    image

    Joint Accreditation Statement:  In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC) and the American Academy of PAs (AAPA) to provide continuing education for the healthcare team.
    image

    AAPA Credit Designation Statement Enduring Material: American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 16 AAPA Category 1 CME credits. Approval is valid until 2/16/2020. PAs should only claim credit commensurate with the extent of their participation. 

    Method of participation in the activity: To be awarded a maximum of AAPA Category 1 CME credits and a Certificate of Completion you must:

    • Review 16 training modules (16 hours) provided in this activity.
    • Earn a passing score of 75% on each of the module’s post-tests.
    • Complete a final evaluation and follow instructions at the end of the course regarding how to retrieve your Certificate of Completion as well as your continuing credit certificate*.

    *Credit will not be awarded unless all components of the program are completed. Partial credit will not be awarded.

    Disclosures: AAAP's CME program aims to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, disclosure information from all series planners and speakers is provided during the planning process to ensure resolution of any identified conflicts. The following PCSS-MAT AAAP staff and CPD Committee members have reported that they have no commercial relationships relevant to the content of this activity to disclose: Dean Krahn, MD, Michael Goedde, MD, Thomas Penders, MD, Alan Gordon, MD, Oliveria Bugunovic, MD, Margi Kotz, MD, Kathryn Cates-Wessel, Justina Andonian and Miriam Giles. Kevin Sevarino, MD owns a small amount of stock in GSK. Content Developers for this 16 hour course disclose the following: https://30qkon2g8eif8wrj03zeh0...

    Disclosure of Unlabeled Medication Use:Faculty have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. AAAP has determined that all scientific research referred to, reported, or used in this course conforms to the generally accepted standards of experimental design, data collection, and analysis.  

    Support for the Program:

    Funding for this initiative was made possible (in part) by grant no. 5U79TI026556 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


  • 8 Hour Online MAT Waiver Training

    Contains 29 Component(s), Includes Credits

    8 hour MAT waiver training course for physicians and physician assistants who wish to apply for a waiver to prescribe buprenorphine. PLEASE NOTE: This is NOT the Half and Half MAT waiver course.

    Target Audience: 

    This activity will assist physicians and physician assistants (PAs) who wish to apply for a waiver to prescribe buprenorphine for the treatment of opioid use disorders.  

    In accordance with the Comprehensive Addiction and Recovery Act (CARA), PAs must complete 24 hours of specialized training to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. This activity will allow PAs to fulfill the 8 hour portion of the 24 hour MAT waiver training requirement.

    Educational Objectives:

    At the conclusion of this activity, learners should be able to:

    • Review addiction identification and evidence-based treatments.
    • Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
    • Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
    • Explain the process of buprenorphine induction as well as stabilization and maintenance.
    • Discuss other approved antagonist and agonist medications to treat OUD.
    • Discuss basic office protocols including medical record documentation and confidentially.
    • Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD. 
    • Apply for a MAT Waiver Training Certificate to begin treating patients with OUD.

    Fee: No cost 

    image

    Joint Accreditation Statement: 

    In support of improving patient care, this activity has been planned and implemented by the American Academy of Addiction Psychiatry. American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    In 2019, AAAP also added accreditation from The American Academy of PAs (AAPA), American Psychological Association (APA) and Association for Social Work Boards (ASWB).

    Credit Designation Statement – Physicians: American Academy of Addiction Psychiatry designates this enduring material for a maximum of 8 (eight) AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Accreditation Release Date: November 30, 2018

    Accreditation Expiration Date: November 30, 2021

     

    image

    AAPA Credit Designation Statement - Enduring Material:

    American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 8 AAPA Category 1 CME credits. Approval is valid until 2/16/2020. PAs should only claim credit commensurate with the extent of their participation. 

    Method of participation in the activity: To be awarded a maximum of 8 AMA PRA Category 1 Credits™ or 8 AAPA Category 1 CME credits and a MAT Waiver Training Certificate you must:

    • Review 8 training modules (8 hours) provided in this activity.
    • Earn a minimum cumulative score of 75% on the examination. Participants will have three opportunities to correctly answer the examination.
    • Complete a final evaluation and follow instructions at the end of the course regarding how to retrieve your Certificate of Completion as well as your continuing education credit certificate*.

    *Credit will not be awarded unless all components of the program are completed. Partial credit will not be awarded.

    Disclosures:

    AAAP's interprofessional continuing education program aims to provide educational information that is balanced, independent, objective and free of bias and based on evidence. During the planning process, anyone that is involved in the content is required to disclose to AAAP and our learners any real or potential conflict of interest related to the educational activity. The following individuals have no relevant financial relationships with an ACCME defined commercial interest to disclose: Thomas Penders, MD, Michael Goedde, MD, Nitigna Desai, MD, Karen Oliver, PhD, John Renner, Jr, MD, Kevin Sevarino, MD, PhD, Stephen Wyatt, DO, Sanchit Maruti, MD, Colleen LaBelle, MSN, RN-BC, CARN, Yngvild Olsen, MD, Kathryn Cates-Wessel, Miriam Giles, Erin Waters, Seth Acton, and Justina Pereira.

    Disclosure of Unlabeled Medication Use:

    Faculty have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. AAAP has determined that all scientific research referred to, reported, or used in this course conforms to the generally accepted standards of experimental design, data collection, and analysis.  

    Support for the Program:

    Funding for this initiative was made possible (in part) by grant no. 5U79TI026556 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.